Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer.


Novel therapeutic agents (NTA) directed against a wide array of newly described molecular targets are now entering clinical investigation, many in the treatment of non-small cell lung cancer (NSCLC). The great majority of these clinical trials have been directed toward patients with advanced stage (metastatic) disease. More recently, study of NTAs has… (More)


4 Figures and Tables

Slides referencing similar topics